Clinical Trial Update: A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion [Phase 1]

View source ↗

Summary

Phase 1 study to evaluate mass balance, metabolism, elimination, and drug levels of radiolabeled BMS-986504 (MRTX1719) in participants with advanced solid tumor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumors

Drugs mentioned

• MRTX1719 (BMS-986504) (BMS-986504)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Advanced Solid Tumors With Homozygous MTAP Deletion | Phase 1 | Status: RECRUITING